Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 01, 2022

SELL
$1.34 - $5.34 $2 - $10
-2 Reduced 0.02%
10,933 $23,000
Q1 2022

May 04, 2022

SELL
$4.58 - $6.8 $4,900 - $7,276
-1,070 Reduced 8.91%
10,935 $48,000
Q4 2021

Feb 07, 2022

BUY
$5.23 - $7.18 $6,626 - $9,097
1,267 Added 11.8%
12,005 $77,000
Q3 2021

Nov 02, 2021

SELL
$5.94 - $8.75 $7,228 - $10,648
-1,217 Reduced 10.18%
10,738 $66,000
Q2 2021

Aug 03, 2021

SELL
$7.54 - $9.79 $2,186 - $2,839
-290 Reduced 2.37%
11,955 $96,000
Q1 2021

May 04, 2021

BUY
$4.76 - $11.25 $58,286 - $137,756
12,245 New
12,245 $118,000
Q2 2020

Aug 07, 2020

SELL
$1.33 - $3.63 $10,383 - $28,339
-7,807 Closed
0 $0
Q1 2020

May 04, 2020

SELL
$1.27 - $2.33 $166 - $305
-131 Reduced 1.65%
7,807 $11,000
Q4 2019

Feb 04, 2020

SELL
$1.3 - $2.72 $2,480 - $5,189
-1,908 Reduced 19.38%
7,938 $13,000
Q3 2019

Nov 12, 2019

BUY
$1.93 - $4.21 $19,002 - $41,451
9,846 New
9,846 $23,000
Q1 2019

May 03, 2019

SELL
$1.79 - $3.12 $819,898 - $1.43 Million
-458,044 Closed
0 $0
Q4 2018

Feb 05, 2019

BUY
$2.24 - $3.9 $402,998 - $701,649
179,910 Added 64.68%
458,044 $1.18 Million
Q3 2018

Nov 01, 2018

SELL
$3.58 - $4.9 $54,201 - $74,186
-15,140 Reduced 5.16%
278,134 $1.08 Million
Q2 2018

Aug 02, 2018

BUY
$4.43 - $5.14 $39,427 - $45,746
8,900 Added 3.13%
293,274 $1.4 Million
Q1 2018

May 04, 2018

BUY
$4.65 - $5.9 $129,967 - $164,905
27,950 Added 10.9%
284,374 $1.48 Million
Q4 2017

Feb 01, 2018

BUY
$4.32 - $5.52 $135,388 - $172,996
31,340 Added 13.92%
256,424 $1.19 Million
Q3 2017

Oct 27, 2017

SELL
$4.35 - $5.25 $19,401 - $23,415
-4,460 Reduced 1.94%
225,084 $1.18 Million
Q2 2017

Aug 07, 2017

BUY
N/A
229,544
229,544 $1.25 Million

Others Institutions Holding CMRX

About CHIMERIX INC


  • Ticker CMRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,622,896
  • Market Cap $85M
  • Description
  • Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...
More about CMRX
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.